These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 24065801)
1. Comment on: Tessari et al. Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. Diabetes 2013;62:2699-2708. Kruszelnicka O; Rakowski T; Surdacki A Diabetes; 2013 Oct; 62(10):e23. PubMed ID: 24065801 [No Abstract] [Full Text] [Related]
2. Response to comment on: Tessari et al. Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. Diabetes 2013;62:2699-2708. Tessari P Diabetes; 2013 Oct; 62(10):e24. PubMed ID: 24065802 [No Abstract] [Full Text] [Related]
3. Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. Tessari P; Cecchet D; Artusi C; Vettore M; Millioni R; Plebani M; Puricelli L; Vedovato M Diabetes; 2013 Aug; 62(8):2699-708. PubMed ID: 23474488 [TBL] [Abstract][Full Text] [Related]
4. ON NO--the continuing story of nitric oxide, diabetes, and cardiovascular disease. Bøtker HE; Møller N Diabetes; 2013 Aug; 62(8):2645-7. PubMed ID: 23881191 [No Abstract] [Full Text] [Related]
6. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Toutouzas K; Riga M; Stefanadi E; Stefanadis C Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879 [TBL] [Abstract][Full Text] [Related]
7. Impact of ADMA (asymmetric dimethylarginine) on physiology with respect to diabetes mellitus and respiratory system BEAS-2B cells (human bronchial epithelial cells). Galal O; Podlogar J; Verspohl EJ J Pharm Pharmacol; 2013 Feb; 65(2):253-63. PubMed ID: 23278693 [TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Zsuga J; Gesztelyi R; Török J; Kéki S; Bereczki D Med Hypotheses; 2005; 65(6):1091-8. PubMed ID: 16125868 [TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Chan NN; Chan JC Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950 [TBL] [Abstract][Full Text] [Related]
10. [Asymmetric dimethyl arginine (ADMA): a novel cardiovascular risk factor?]. Stühlinger M Wien Med Wochenschr; 2007 Feb; 157(3-4):57-60. PubMed ID: 17340060 [TBL] [Abstract][Full Text] [Related]
11. Effect of asymmetric dimethylarginine (ADMA) on heart failure development. Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818 [TBL] [Abstract][Full Text] [Related]
12. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology]. Sela BA Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539 [TBL] [Abstract][Full Text] [Related]
13. Comment: the asymmetrical dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in the regulation of nitric oxide generation. Vallance P Clin Sci (Lond); 2001 Feb; 100(2):159-60. PubMed ID: 11171284 [No Abstract] [Full Text] [Related]
14. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Grasemann H; Al-Saleh S; Scott JA; Shehnaz D; Mehl A; Amin R; Rafii M; Pencharz P; Belik J; Ratjen F Am J Respir Crit Care Med; 2011 May; 183(10):1363-8. PubMed ID: 21278301 [TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rats. Yang ZC; Xia K; Wang L; Jia SJ; Li D; Zhang Z; Deng S; Zhang XH; Deng HW; Li YJ Microvasc Res; 2007 Mar; 73(2):131-6. PubMed ID: 17098259 [TBL] [Abstract][Full Text] [Related]
16. Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. Pleiner J; Mittermayer F; Langenberger H; Winzer C; Schaller G; Pacini G; Kautzky-Willer A; Tura A; Wolzt M Wien Klin Wochenschr; 2007; 119(15-16):483-9. PubMed ID: 17721768 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. Soro-Paavonen A; Zhang WZ; Venardos K; Coughlan MT; Harris E; Tong DC; Brasacchio D; Paavonen K; Chin-Dusting J; Cooper ME; Kaye D; Thomas MC; Forbes JM J Hypertens; 2010 Apr; 28(4):780-8. PubMed ID: 20186099 [TBL] [Abstract][Full Text] [Related]
18. Increased activity in the nitric oxide pathway during chronic euglycemic hyperinsulinemia in the rat. Moreau P; Yamaguchi N; de Champlain J J Hypertens Suppl; 1993 Dec; 11(5):S270-1. PubMed ID: 8158380 [No Abstract] [Full Text] [Related]